January 17, 2023

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

About This Episode

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm, host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative.  They discuss the immediate implications of the drug approval, how it will impact the Alzheimer’s movement, and what it means for the future of Alzheimer’s disease. 

Do you have feedback or an idea for the podcast? Send us a note at BrainStorm@usagainstalzheimers.org.
 

Support the show

BrainStorm Feed

69

Music and Mind Series – Part 3 with Connie Tomaino

How does someone with a movement disorder that effects executive functioning suddenly move to music with a dance tempo?  Concetta M.

LISTEN NOW
68

Music and Mind Series – Part 2 with Connie Tomaino

How can someone with supposedly no memory recognize a familiar melody?
LISTEN NOW
67

Dr. Dean Ornish – Lifestyle Changes and the Reversal of Alzheimer’s Symptoms (part 2)

Lifestyle interventions like diet and exercise can reduce the risk of developing dementia. A recent study by Dr.

LISTEN NOW